![](https://news.europawire.eu/wp-content/uploads/2023/03/OncoC4-licenses-next-generation-anti-CTLA-4-monoclonal-antibody-candidate-to-BioNTech-144x144.jpg)
(IN BRIEF) Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older. Pending final approval from the European Commission, the vaccine will … Read the full press release